Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $40

Benzinga Newsdesk www.benzinga.com Positive 83.5%

Neg 0% Neu 0% Pos 83.5%

Canaccord Genuity analyst Maria Ripps maintains Hims & Hers Health (NYSE:HIMS) with a Buy and raises the price target from $32 to $40.